Use of sedatives and muscle relaxants in newborn babies receiving mechanical ventilation

Malcolm I Levene, Michael W Quinn

In the 1970s sedation or paralysis was rarely considered to be necessary in the ventilatory care of premature infants. We now recognise that infants who 'fight' the ventilator may be at increased risk of a number of important neonatal complications such as intraventricular haemorrhage and pneumothorax. There is no consensus view on the best way of managing these infants, nor what pharmacological preparations to use in reducing the risks of these complications. When formulating an approach to inhibiting spontaneous respiration in the ventilated neonate there are three important issues to be considered. These are (i) what are the hazards of the infant breathing out of synchrony with the ventilator?, (ii) what are the effects of stress and pain associated with mechanical ventilation?, and (iii) what are the possible adverse effects of drugs used to reduce struggling or stress?

The baby and the ventilator
Anyone involved in mechanical ventilation of infants will recognise the infant who 'fights' the ventilator. Defining this is somewhat more difficult. Greenough et al identified infants who were actively expiring at the time of ventilator inflation as being particularly at risk of developing pneumothorax. They used an intraoesophageal balloon to detect spontaneous respiratory activity and a pneumotachograph to measure tidal flow. This system is neither available nor practicable in most newborn units and other methods to recognise this pattern have been adopted. The simplest is observing the baby's respiratory activity in relation to the mechanical ventilator. Although this may successfully identify some babies, particularly those who are vigorously breathing (usually mature newborn infants) or those who are mechanically ventilated at slow rates, the observer may be in some doubt as to the interaction between baby and machine. An alternative method is to examine the beat-to-beat variability on an undamped arterial blood pressure trace. When an infant breathes out of phase with the ventilator there is increased fluctuation between the maximum and minimum systolic peaks, and if the coefficient of variation exceeds 10% we believe that this represents 'fighting'. In practice, observation alone of the blood pressure trace confirms the clinical impression of the baby showing this pattern.

Perlman et al showed that ventilated infants who had a fluctuating pattern of cerebral blood flow velocity (CBFV) in the anterior cerebral artery were at increased risk of subsequently developing intraventricular haemorrhage (IVH). This fluctuating pattern directly reflected fluctuating arterial blood pressure as discussed above. They suggested that interventions to reduce fluctuating CBFV may reduce the incidence of IVH.

We assume that intensive care is an abnormally stressful event for newborn infants. There are many interrelated components of stress which are not understood and have not yet been unravelled.

It is likely that 'fighting' the ventilator is one factor in the stress situation. Adults who have been pharmacologically paralysed to facilitate mechanical ventilation and who become aware describe it as being a very frightening experience. This may be compounded by painful procedures undertaken on the paralysed, but aware, patient. It is not unreasonable to believe that the newborn may be similarly stressed by neuromuscular paralysis in an 'awake' state.

Muscle relaxants
Pancuronium is a steroidal non-depolarising muscle relaxant and was the first to become widely used in clinical practice. It is metabolised in the liver and the metabolites are excreted mainly in the urine. Because of the dependence of this drug on liver metabolism and renal excretion, the length of action will be prolonged in premature infants with immature renal and hepatic function. Infants and children are more sensitive to the drug than adults and take longer to clear it.

CLINICAL ROLE OF PANCURONIUM
Perlman et al showed that muscle paralysis of babies with a fluctuating CBFV pattern led to a significant reduction in the incidence of IVH. Those paralysed infants who developed IVH did so after the cessation of paralysis. In a larger randomised case control study of unselected babies, Bancalari et al (abstract, Pediatric Res 1980; 14: A986) failed to demonstrate a protective effect of pancuronium in IVH. The infants who were paralysed actually had a significantly higher incidence of massive IVH. We have similarly failed to find a reduction in IVH in paralysed infants.
Greenough et al selectively paralysed infants with pancuronium who actively expired against positive pressure inspiration. All the infants who were not paralysed developed a pneumothorax while only one of the 11 who were paralysed did so. The authors suggested that muscle paralysis should only be used in selected patients 'in view of the psychological problems for parents associated with use of paralysing agents'. Cooke and Rennie reviewed the incidence of pneumothorax in their unit before and after the use of muscle paralysis for ventilated newborn infants who struggled against the ventilator. They showed a reduction in the incidence of pneumothorax in infants with a gestation age ≥27 weeks when pancuronium was used. Bancalari, found no reduction in the incidence of pneumothorax in a large randomised study of all ventilated newborn infants. Pollitzer et al similarly found no reduction in the rate of pneumothorax in an unselected group of ventilated infants who were paralysed. It is not possible to agree on the clinical indication for pancuronium in the prevention of pneumothorax, but there appears to be good evidence that it does prevent pneumothorax in selected cases. Unfortunately, the criteria for this selection are difficult to apply on a regular basis in a busy neonatal unit.

Pollitzer et al have shown a significant reduction in the incidence of chronic lung disease in ventilated infants who were paralysed. All ventilated infants with hyaline membrane disease were entered into this trial, with no selection criteria. A recent study has shown an increase in pulmonary resistance and reduction in dynamic pulmonary compliance in paralysed infants. This was not a controlled study and the changes may have been due to natural progression of the disease process. None the less, there was a close temporal association between starting and discontinuing pancuronium, and deterioration and improvement in pulmonary function tests respectively. A suggested explanation for this was a loss of negative intrapleural pressure leading to impairment of drainage of lung fluid.

It may not be necessary to use any drugs to improve synchrony with the ventilator. The Cambridge group have shown that careful alterations in ventilator settings may allow the ventilator to 'capture' the infant's own respiratory efforts. This in practice is time consuming and is not likely to be practical in the setting of junior medical staff making most of the ventilator adjustments in a busy neonatal unit.

POTENTIAL SIDE EFFECTS
Pancuronium causes complete loss of muscle power and ventilatory effort. If this is not anticipated, severe hypotension may result from inadequate chest wall movement. Studies suggest that, although the acute effects of pancuronium on oxygenation are unpredictable, it does appear to reduce the variability in gas exchange over a more prolonged period.

The cardiovascular effects of pancuronium are variable. Pancuronium should not alter blood pressure as ganglion blockade and histamine release are negligible. One case report suggested that pancuronium could cause severe hypotension, but clinical studies of its effect on blood pressure and heart rate have shown no consistent trend. A commonly observed effect of long term pancuronium administration is that infants become oedematous. Greenough et al found that paralysed infants regained their birth weight sooner than non-paralysed controls despite fluid restriction. A suggested mechanism was hypoperfusion of the kidneys resulting in relative oliguria. This was supported by the higher urinary osmolarity in the paralysed infants. Long term paralysis may lead to chest wall oedema and impaired compliance. The development of joint contractures has also been reported.

Drugs for sedation and analgesia
Another approach is to inhibit the baby's respiratory drive with opioid drugs. Morphine has been the most widely used in this context. Understanding the metabolism and disposition of these drugs is essential if side effects are to be avoided. These include hypotension, reduced gut motility, muscle rigidity, and fits. Morphine is metabolised in the liver by glucuronidation and sulphation with the products being excreted in the urine. Morphine-3-glucuronide (M3G) is an inactive metabolite but there is evidence that morphine-6-glucuronide (M6G) is a more potent analgesic than morphine itself and may have a more profound respiratory depressant effect. It is often present in plasma in greater amounts than the parent morphine molecule. The analgesic properties of morphine may be largely dependent on the rate of conversion to M6G. Both the rate of clearance of morphine and the rate of metabolism to M6G are impaired in neonates. Therefore, higher levels of morphine are likely to accumulate but conversion to M6G will be less efficient. M6G is excreted by the kidneys and poor renal function may lead to accumulation of this metabolite in premature newborn infants. It is unclear whether these factors would result in enhanced or impaired analgesic activity of morphine in the newborn.

CLINICAL ROLE OF OPIOIDS
There is anecdotal evidence that the newborn infant is more sensitive to the respiratory depressant properties of morphine. This may be related to impaired metabolism and/or increased penetration into the brain. There is little published data on the effectiveness of morphine in improving synchrony in ventilated neonates but our clinical impression has been that morphine, even in high doses, may not suppress the infant's ventilatory effort sufficiently to improve synchrony.

Diamorphine, which is metabolised to morphine, has recently been carefully evaluated in the newborn infant. It has a rapid onset of action and is more potent than morphine. A
dose regimen at the lower end of that for morphine was used because of its higher potency. A bolus dose of 50 μg/kg was followed by an infusion rate of 15 μg/kg/hour. There was a positive correlation between clearance and gestational age. Careful monitoring of blood pressure showed a small but significant fall and there was reduction in respiratory rate which was taken to indicate improved synchrony with the ventilator.

Fentanyl and alfentanil are synthetic opioid analgesics which are considerably more potent than morphine. They have the theoretical advantages of shorter duration of action and greater cardiovascular stability because of less histamine release. These advantages have made them attractive for use in the neonatal period, particularly if the shorter duration of action allows for quicker weaning from the ventilator. Marlow et al used a loading dose of alfentanil of 15–20 μg/kg followed by infusion of 3–5 μg/kg/hour in ventilated preterm infants. These infants had reduced clearance and a prolonged elimination half life when compared with older children and adults but there was marked variability in metabolism between individuals.

ANALGESIA
The measurement of analgesic efficacy is difficult in the ventilated premature newborn. There is some evidence from pain studies in infants that the concentration of morphine required to produce analgesia is higher in older children. The reason for this is not clear. There is no information on analgesic concentrations of morphine in premature neonates. Even if these data were available, the variation in the metabolism of morphine and the analgesic effect of its metabolites would make the accurate determination of an appropriate dosage regimen difficult.

Pain in the newborn infant may be measured using behavioural, physiological, and endocrine responses. It is difficult to assess the relationship between the concentration of morphine and the analgesic effect of its metabolites. Therefore, the accurate determination of an appropriate dosage regimen is difficult.

Pain in the newborn infant may be assessed using behavioural, physiological, and endocrine responses. It is difficult to interpret in a sick infant. Humoral and endocrine markers may provide useful information. Anand et al demonstrated a marked endocrine response in infants undergoing surgery for patent ductus arteriosus who had not received adequate analgesia. There was an increase in adrenaline, noradrenaline, and glucagon, with a reduction in insulin concentrations. These changes were ablated by preoperative treatment with fentanyl. There was also evidence that those who received fentanyl had fewer postoperative complications. The same workers had earlier shown a graded endocrine response depending on whether the infants where subjected to mild, moderate, or severe surgical stress.

We have recently reported a randomised study comparing the effects of morphine alone (50–100 μg/kg/hour by infusion), pancuronium alone (100 μg/kg/dose, as required), and a combination of morphine and pancuronium in reducing catecholamine concentrations in struggling ventilated neonates (abstract presented at the British Paediatric Association meeting, Warwick 1991.) Those who received morphine showed a significant reduction in noradrenaline concentrations while those who received pancuronium alone or pancuronium with morphine showed no such reduction. The reduction in noradrenaline concentrations was modest and much less than those reported in Anand’s moderate and severe surgical groups. A number of infants were withdrawn from the morphine arm of the trial because the infants continued to struggle, probably because no loading dose was used. We concluded that infants who settle on morphine show a significant reduction in stress hormone concentrations.

Although it is not known whether intubation and ventilation are painful for premature newborn infants, behavioural clues that an infant feels pain, such as withdrawal and grimacing, are absent in paralysed infants. It may then be forgotten that procedures undertaken in paralysed ‘awake’ infants are painful. This may be an additional important reason for giving continuous analgesic medication to paralysed infants.

POTENTIAL SIDE EFFECTS
Although, theoretically, opiates may prolong the length of time spent on the ventilator, we found no significant difference in the number of ventilator days between morphine and pancuronium treated infants in our randomised trial.

Hypotension is a serious potential complication of morphine. We have carefully monitored infants for this complication and found no reduction in blood pressure six hours after starting morphine by continuous infusion. Continuous blood pressure monitoring in a group of eight infants who received a bolus dose of morphine of 400 μg/kg over two hours showed no evidence of hypotension. This may be because the bolus dose was given over a prolonged period. Marlow et al found a transient but significant reduction in blood pressure when a bolus of alfentanil was given over two minutes. The rate of drug administration is probably important.

Muscle rigidity is a reported complication of opiate administration. Despite careful observation over the last few years we have only observed this effect transiently in two infants. Fits after morphine have been described in two neonates who were on standard rates of morphine infusion (32 and 40 μg/kg/hour) and the drug concentrations were not high (61 and 90 μg/l). Similar concentrations have been reported without the occurrence of seizures. This may have been an idiosyncratic response and has not been subsequently reported.

Withdrawal symptoms may occur after prolonged administration of any opiate, but these are unlikely after short courses usually given to ventilated neonates. We have not recognised withdrawal symptoms in a newborn infant given morphine for therapeutic indications. A recent study has shown that withdrawal symptoms are much more common.
after fentanyl than morphine. The symptom score was that used to assess term infants of narcotic addicted mothers. This is an entirely different group of infants on which it may not be appropriate to use the same symptom score. This may explain the high incidence of withdrawal symptoms in both groups despite careful tapering of the dose.

The endogenous opiate receptors appear to be functional in the immature nervous system and we do not know whether there may be long term effects of high concentration infusion of exogenous opiates such as morphine. The functional integrity of the endogenous opiate system must be further studied for long term effects after cessation of the infusion.

Current practice
The evidence that muscle paralysis prevents IVH is poor and its role in preventing pneumothorax is uncertain. At present we use pancuronium sparingly. The indications include mature babies (>34 weeks) who make vigorous respiratory efforts and whose ventilatory efforts are clearly detrimental to gas exchange. This decision is made clinically depending on how much the infant’s respiratory effort is out of synchrony with the ventilator and the variability of the arterial blood pressure trace. Paralysis is frequently employed after thoracic surgery where an anastomosis may be torn if the infant struggles (for example, a repair of oesophageal atresia). If a paralysed infant is likely to need long term ventilation or be subjected to painful procedures, then a simultaneous morphine infusion is continued for at least four days.

We feel that infants with hyaline membrane disease who have received exogenous surfactant (Curosurf, Chiesi Pharmaceuticals, in our unit) might better tolerate a considerably less paralysed infant. There is often a rapid fall in the baby’s oxygen requirements after the administration of this type of surfactant, probably reflecting the change in lung compliance.

We consider that ‘awake’ intubation and ventilation exacerbates the infant’s stress responses and therefore we start on morphine every infant who is likely to need ventilation for more than a few hours. A combination of bolus followed by infusion will ensure that an adequate plasma concentration is reached quickly and maintained. We administer the bolus dose over two hours to reduce the risk of adverse effects. From published data on volume of distribution and clearance, we have calculated a dosage regimen that aims to achieve a plasma concentration of 100 μg/kg/hour. This is higher than the level shown to be analgesic in older children (65 μg/kg) and aims to produce respiratory depression. Because of wide interindividual variation, this figure can only be an approximation. Our present protocol is to give 100 μg/kg/hour for two hours followed by a continuous infusion of 25 μg/kg/hour. We continue the infusion until the inspired oxygen concentration is less than 40%. Because this should achieve adequate analgesic concentrations quickly, we feel that the baby is protected from repeated painful procedures such as venepuncture and heel stabs. The dose of analgesics is therefore likely to be extremely painful and we do recommend that local anaesthetic is infiltrated superficially and into the deep tissues before insertion of the drain.

10 McIntosh N. Hypotension associated with pancuronium use in the newborn. Lancet 1985;i:279.
Use of sedatives and muscle relaxants in newborn babies receiving mechanical ventilation.
M I Levene and M W Quinn

Arch Dis Child 1992 67: 870-873
doi: 10.1136/adc.67.7_Spec_No.870

Updated information and services can be found at:
http://adc.bmj.com/content/67/7_Spec_No/870.citation

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/